Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 18/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31511677 | 0.87 | GPR119 (0.39) | GPR119NAMPT | |
| SCHEMBL22835974 | 0.83 | GPR119 (0.52) | GPR119NAMPT | |
| SCHEMBL25547332 | 0.82 | GPR119 (0.60) | GPR119NAMPTCYP2C9 | |
| SCHEMBL31511594 | 0.82 | ALDH1A1 (0.39) | GPR119 | |
| SCHEMBL30451669 | 0.82 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL14316367 | 0.82 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL20077751 | 0.82 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL15203186 | 0.82 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL16466415 | 0.81 | GPR119 (0.52) | GPR119NAMPT | |
| SCHEMBL14316365 | 0.80 | GPR119 (0.53) | GPR119NAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20240217983-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4320129-A1 | GPR119 AGONISTS | Kallyope, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2022216709-A1 | GPR119 AGONISTS | KALLYOPE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2018071317-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018071315-A2 | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018068296-A1 | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | GPR119 15/4885NAMPT 4040/4885CYP2C9 127/4885 |
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, ADRB1 | GPR119 7/4885NAMPT 3925/4885CYP2C9 642/4885 |
| US-20240217983-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | GPR119 1/4885NAMPT 1084/4885CYP2C9 2350/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | GPR119 15/4885NAMPT 4040/4885CYP2C9 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.